Department of Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital, Incheon, Korea.
Cancer Sci. 2012 Feb;103(2):296-304. doi: 10.1111/j.1349-7006.2011.02170.x. Epub 2012 Jan 19.
This study explored the combined effect of number and pattern of mutations in the X/precore regions of the hepatitis B virus (HBV) genome, mutational complex genotype (MCG), on hepatocellular carcinoma (HCC) development. Sequence variations were determined by direct sequencing and multiplex restriction fragment mass polymorphism analysis in 150 age-, sex- and hepatitis B e antigen (HBeAg) status-matched patients with and without HCC. In addition, a longitudinal study and an external validation of MCG were conducted. All were HBV subgenotype C2. Eight high-frequency mutations (G1613A, C1653T, T1753V, A1762T, G1764A, A1846T, G1896A and G1899A) were significantly associated with HCC. Whereas C1653T, T1753V, G1764A and A1846T were independent mutational factors for HCC, the significance of these individual mutations was negligible when analyzed with all clinico-virological variables. The total number of mutations was the only independent viral factor for HCC, irrespective of HBeAg status. There was a significant dose-risk relationship between the number of mutations and HCC, in which high risks for HCC were associated with mutation numbers ≥ 6. Pattern analysis of the mutations revealed disparity in distribution among the top seven high-risk mutation combination patterns, which accounted for 40 and 2.7% of HCC and non-HCC cases, respectively. The predictive accuracy of the high-risk mutations for HCC was similar to that of α-fetoprotein. Longitudinal and external validation studies also supported the association of mutation number with HCC development. MCG in the HBV X/precore regions is a risk indicator for HCC, and might serve as a new guide to the HCC screening scheme for chronic HBV carriers.
本研究探讨了乙型肝炎病毒 (HBV) 基因组 X/precore 区突变数量和模式(即突变复杂基因型,MCG)对肝细胞癌 (HCC) 发展的联合影响。通过直接测序和多重限制片段质量多态性分析,在 150 名年龄、性别和乙型肝炎 e 抗原 (HBeAg) 状态匹配的 HCC 患者和非 HCC 患者中确定了序列变异。此外,还进行了 MCG 的纵向研究和外部验证。所有患者均为 HBV 亚基因型 C2。8 种高频突变 (G1613A、C1653T、T1753V、A1762T、G1764A、A1846T、G1896A 和 G1899A) 与 HCC 显著相关。尽管 C1653T、T1753V、G1764A 和 A1846T 是 HCC 的独立突变因素,但当与所有临床病毒学变量一起分析时,这些单个突变的意义可以忽略不计。突变总数是 HCC 的唯一独立病毒因素,与 HBeAg 状态无关。突变数量与 HCC 之间存在显著的剂量-风险关系,突变数量≥6 与 HCC 发生的高风险相关。突变模式分析显示,前 7 种高风险突变组合模式之间的分布存在差异,这些模式分别占 HCC 和非 HCC 病例的 40%和 2.7%。高危突变对 HCC 的预测准确性与甲胎蛋白相似。纵向和外部验证研究也支持了突变数量与 HCC 发展之间的关联。HBV X/precore 区的 MCG 是 HCC 的风险指标,可能成为慢性 HBV 携带者 HCC 筛查方案的新指南。